


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the above-referenced patent application. Support for the amendments follows the listing of the claims.

Listing of the Claims:

1-42. (Canceled)

43. (Currently Amended) A method for treating a disease or condition in a patient resulting from the presence of neoplastic tissue comprising providing the patient with a therapeutically effective amount of a compound of Formula 1:



Formula 1

wherein M represents a metal cation selected from Gd^{+3} or Lu^{+3} ;

AL is an apical ligand with the proviso that AL is not derived from acetic acid, nitric acid, or hydrochloric acid; n is 2;

R^1 , R^{1a} , R^2 , R^3 , R^4 , R^{4a} , R^7 , R^8 , R^{10} , R^{11} , R^{12} , and R^{13} are independently selected from hydrogen, acyl, acyloxy, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted amino, optionally substituted aryl, optionally substituted aryloxy, carboxyl, (optionally substituted alkoxy)carbonyl, (optionally substituted amino)carbonyl, (optionally substituted amino)carbonyloxy, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heteroaryl, optionally substituted heteroaryloxy, optionally substituted heterocyclyl, optionally substituted heterocyclooxy, and hydroxyl; and R^6 and R^9 are hydrogen; and providing the patient with a chemotherapeutic compound, or providing the area in proximity to the neoplastic tissue with a therapeutic energy means selected from photoirradiation and ionizing radiation.

44. (Previously Presented) The method of claim 43, wherein M is Gd^{3+} .
45. (Previously Presented) The method of claim 44, wherein R^{10} , R^{11} , R^{12} , and R^{13} each hydrogen.
46. (Previously Presented) The method of claim 45, wherein R^1 and R^{1a} are identical, and R^4 and R^{4a} are identical.
47. (Currently Amended) The method of claim 43, [further] comprising providing the patient with ionizing radiation.
48. (Previously Presented) The method of claim 43, wherein the apical ligand is selected from the group consisting of sugar derivatives, cholesterol derivatives, PEG acids, organic acids, organosulfates, organophosphates, phosphates or inorganic ligands.
49. (Previously Presented) The method of claim 49, wherein the apical ligand is derived from an acid selected from the group consisting of gluconic acid, glucuronic acid, cholic acid, deoxycholic acid, methylphosphonic acid, phenylphosphonic acid, phosphoric acid, formic acid, propionic acid, butyric acid, pentanoic acid, 3,6,9-trioxodecanoic acid, 3,6-dioxoheptanoic acid, 2,5-dioxoheptanoic acid, methylvaleric acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzoic acid, salicylic acid, 3-fluorobenzoic acid, 4-aminobenzoic acid, cinnamic acid, mandelic acid, and p-toluene-sulfonic acid.
50. (Previously Presented) The method of claim 46, wherein the therapeutically effective amount of the compound of Formula 1 is provided in an amount between about 3 to about 15 mg/kg of patient body weight.
51. (Previously Presented) The method of claim 46, wherein the therapeutically effective amount of the compound of Formula 1 is provided in an amount between about 1 to about 7 mg/kg of patient body weight.
52. (Previously Presented) The method of claim 43, wherein the therapeutically effective amount of the compound of Formula 1 is provided in multiple doses.
53. (Previously Presented) The method of claim 43, wherein the therapeutically effective amount of the compound of Formula 1 is provided in a dosage form selected from the group consisting of osmotic pump systems, dissolution systems, suppository, liquid solutions, suspensions, and emulsions.

54. (Previously Presented) The method of claim 43, further comprising administering an additional therapeutic agent.

55. (Previously Presented) The method of claim 54, wherein the additional therapeutic agent is sedative, narcotic, anti-emetic or analgesic.

56. (Previously Presented) The method of claim 55, wherein the additional therapeutic agent is administered topically, intradermally, or subcutaneously.

57. (Previously Presented) The method of claim 43, wherein the providing of the therapeutically effective amount of the compound of Formula 43 is selected from the group consisting of intra-arterial injection, intravenously, intraperitoneally, rectally, parenterally, intramuscularly, or subcutaneously.

58. (Previously Presented) The method of claim 57, wherein the providing of therapeutically effective amount of the compound of Formula 1 is intravenously.

59. (Previously Presented) The method of claim 43, wherein the therapeutically effective amount of a compound of Formula 1 is produced by apical ligand exchange of a metallotexaphyrin apical ligand (AL₁) with an excess of apical ligand (AL)_H.

60. (Previously Presented) The method of claim 59, wherein AL₁ is acetate.

61. (Previously Presented) The method of claim 58, wherein the metallotexaphyrin apical ligand is provided to the patient in the form of an intravenous solution.

62. (Previously Presented) The method of claim 61, wherein AL₁ is acetate.

63. (Previously Presented) The method of claim 59, wherein the (AL) is selected from the group consisting of sugar derivatives, cholesterol derivatives, organic acids, organosulfates, organophosphates, phosphates or inorganic ligands.

64. (Previously Presented) The method of claim 63, wherein AL₁ is acetate.

65. (Previously Presented) The method of claim 64, wherein the apical ligand is phosphate.

66. (Previously Presented) The method of claim 59, wherein the apical ligand exchange results in a higher solubility of the therapeutically effective amount of the compound of Formula 1.

67. (Previously Presented) The method of claim 59, wherein the apical ligand exchange results in higher uptake of the therapeutically effective amount of the compound of Formula 1 in a tissue.

68. (Previously Presented) The method of claim 59, wherein the apical ligand exchange results in lower aggregation of the therapeutically effective amount of the compound of Formula 1.

69. (Previously Presented) The method of claim 59, wherein the apical ligand exchange results in low in vivo toxicity of the therapeutically effective amount of the compound of Formula 1.

70. (Previously Presented) The method of claim 43, wherein the disease or condition resulting from the presence of neoplastic tissue is carcinoma.

71. (Previously Presented) The method of claim 70, wherein the carcinoma has metastasized to at least a portion of the brain of the patient.